According to the National Medical Products Administration website, the National Forestry and Grassland Administration, the National Administration of Traditional Chinese Medicine, and the National Medical Products Administration issued a notice on effectively strengthening the protection and management of pangolins. It pointed out that the commercial import and export of pangolins and their products will continue to be suspended, and the inclusion of pangolin slices in medical insurance will also continue to be suspended; drugs containing pangolin ingredients must not be newly added to the medical insurance category.